How many hospitalizations has the COVID-19 vaccination already prevented in São Paulo?

Izbicki, Rafael; Bastos, Leonardo Soares; Izbicki, Meyer; Lopes, Hedibert F.; Santos, Tiago Mendonça dos

doi:10.6061/clinics/2021/e3250

Cited by 6 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The SIVEP-Flu system has been in use since 2009 (having been implemented in response to the 2009 influenza H1N1 pandemic) and has since centralized the reporting of respiratory viruses and SARI for the Brazilian Ministry of Health (de Souza et al 2020 ). This dataset has been used in several previous studies (Hillesheim et al 2020 ; Baqui et al 2020 , 2021 ; de Souza et al 2020 ; Kawa et al 2021 ; Ranzani et al 2021 ; Izbicki et al 2021 ; Freitas et al 2021 ; Boschiero et al 2022 ; Zeiser et al 2022 ; Sansone et al 2022 ). The patients’ characteristics were included in the individual registration form by the health professional who managed the patients.…”

Section: Methodsmentioning

confidence: 99%

Clinical characteristics and comorbidities of COVID-19 in unvaccinated patients with Down syndrome: first year report in Brazil

et al. 2022

View full text Add to dashboard Cite

Patients with Down syndrome (DS) are more affected by the Coronavirus Disease (COVID)-19 pandemic when compared with other populations. Therefore, the primary aim of our study was to report the death (case fatality rate) from SARS-CoV-2 infection in Brazilian hospitalized patients with DS from 03 January 2020 to 04 April 2021. The secondary objectives were (i) to compare the features of patients with DS and positive for COVID-19 (G1) to those with DS and with a severe acute respiratory infection (SARI) from other etiological factors (G2) to tease apart the unique influence of COVID-19, and (ii) to compare the features of patients with DS and positive for COVID-19 to those without DS, but positive for COVID-19 (G3) to tease apart the unique influence of DS. We obtained the markers for demographic profile, clinical symptoms, comorbidities, and the clinical features for SARI evolution during hospitalization in the first year of the COVID-19 pandemic in Brazil from a Brazilian open-access database. The data were compared between (i) G1 [1619 (0.4%) patients] and G2 [1431 (0.4%) patients]; and between (ii) G1 and G3 [222,181 (64.8%) patients]. The case fatality rate was higher in patients with DS and COVID-19 (G1: 39.2%), followed by individuals from G2 (18.1%) and G3 (14.0%). Patients from G1, when compared to G2, were older (≥ 25 years of age), presented more clinical symptoms related to severe illness and comorbidities, needed intensive care unit (ICU) treatment and non-invasive mechanical ventilation (MV) more frequently, and presented a nearly two fold-increased chance of death (OR = 2.92 [95% CI 2.44–3.50]). Patients from G1, when compared to G3, were younger (< 24 years of age), more prone to nosocomial infection, presented an increased chance for clinical symptoms related to a more severe illness; frequently needed ICU treatment, and invasive and non-invasive MV, and raised almost a three fold-increased chance of death (OR = 3.96 [95% CI 3.60–4.41]). The high case fatality rate in G1 was associated with older age (≥ 25 years of age), presence of clinical symptoms, and comorbidities, such as obesity, related to a more severe clinical condition. Unvaccinated patients with DS affected by COVID-19 had a high case fatality rate, and these patients had a different profile for comorbidities, clinical symptoms, and treatment (such as the need for ICU and MV) when compared with other study populations. Supplementary Information The online version contains supplementary material available at 10.1007/s00439-022-02468-3.

show abstract

Section: Methodsmentioning

confidence: 99%

Clinical characteristics and comorbidities of COVID-19 in unvaccinated patients with Down syndrome: first year report in Brazil

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The only estimates available are for the state of São Paulo, the most populous state with the highest GDP in Brazil. 17 Around 24 thousand hospitalisations and 11 thousand deaths have been averted by vaccinations in São Paulo in the age group of >65 years between February 8 and May 28 of 2021, reducing hospitalisation costs by US$287 million. 17 Thus, our objective was to expand these analyses to the whole country, also accounting for other possible scenarios of vaccination roll-outs.…”

Section: Introductionmentioning

confidence: 99%

“… 17 Around 24 thousand hospitalisations and 11 thousand deaths have been averted by vaccinations in São Paulo in the age group of >65 years between February 8 and May 28 of 2021, reducing hospitalisation costs by US$287 million. 17 Thus, our objective was to expand these analyses to the whole country, also accounting for other possible scenarios of vaccination roll-outs. Previous research shows the deaths of individuals above 80 y.o.…”

Section: Introductionmentioning

confidence: 99%

Estimating the impact of implementation and timing of the COVID-19 vaccination programme in Brazil: a counterfactual analysis

Ferreira

Marquitti

Silva

et al. 2023

The Lancet Regional Health - Americas

Self Cite

View full text Add to dashboard Cite

“…However, information about the effectiveness of the current vaccination campaign was in preventing hospitalisations and deaths countrywide, the main purpose of the developed vaccines, still lacks a proper estimation. The only estimates available are for the São Paulo State, the most populous State with the highest GDP in Brazil [15]. Around 24 thousand hospitalisations and 11 thousand deaths have been averted by vaccination in São Paulo state in the age group of 65+ between February 8 and May 28 of 2021, reducing hospitalisation costs in US$ 287 millions [15].…”

Section: Introductionmentioning

confidence: 99%

Estimating the impact of implementation and timing of the COVID-19 vaccination programme in Brazil: a counterfactual analysis

Ferreira¹,

Marquitti

Silva³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

The vaccines developed in 2020-2021 against the SARS-CoV-2 virus were designed to prevent severity and deaths due to COVID-19. However, how effective this vaccination campaign was at saving lives remains a methodological challenge. In this work, we developed a Bayesian statistical model to estimate the number of deaths and hospitalizations in individuals above 60 years old in Brazil. Using the actual number of hospitalized and deaths from the Brazilian database, and also the coverage of second dose according to the National Immunization Program, we rebuilt the realized scenario as well as the hypothetical scenario without vaccination in Brazil in order to perform a counterfactual analysis. By computing the difference between the hypothetical and realized scenarios, we were able to estimate the direct effect of COVID-19 vaccination in Brazil. We also evaluated two other hypothetical, but not impossible, scenarios considering earlier vaccination roll-outs. We estimated that more than 165 thousand of 60+ years old individuals were not hospitalized due to COVID-19 until August 28, 2021, and other approximately 100 thousand individuals could not have been hospitalized if the immunization started as soon it was approved in Brazil. We also estimate that more than 75 thousand lives were saved in the period analysed for the same age group, and additional 48 thousand lives could have been saved if the Brazilian Government started the immunization 8 weeks earlier.

show abstract

How many hospitalizations has the COVID-19 vaccination already prevented in São Paulo?

Cited by 6 publications

References 2 publications

Clinical characteristics and comorbidities of COVID-19 in unvaccinated patients with Down syndrome: first year report in Brazil

Clinical characteristics and comorbidities of COVID-19 in unvaccinated patients with Down syndrome: first year report in Brazil

Estimating the impact of implementation and timing of the COVID-19 vaccination programme in Brazil: a counterfactual analysis

Estimating the impact of implementation and timing of the COVID-19 vaccination programme in Brazil: a counterfactual analysis

Contact Info

Product

Resources

About